CTOs on the Move

NeuroBo Pharmaceuticals

www.neurobopharma.com

 
NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NeuroBo Pharmaceuticals raised $10M on 01/19/2021

Similar Companies

TearClear

TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.

Skinvisible Pharmaceuticals

Skinvisible Pharmaceuticals is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kiel Laboratories

Kiel Laboratories, Inc. is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nystrom & Associates

Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.